

Moving forward with a new Editorial team for *Thrombosis and Haemostasis*

Christian Weber¹; Gregory Y. H. Lip²

¹Institute for Molecular Cardiovascular Research (IMCAR), RWTH Aachen University, Aachen, Germany; ²Haemostasis Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK

With the first issue of 2010, volume 103, the successful tenure of Klaus T. Preissner as the Editor-in-Chief of *Thrombosis and Haemostasis* over the past seven years has come to a worthy close. While he continues to serve as a Section Editor, his dedicated service and continuous hard work for the journal have earned him a well deserved rest from his Editor-in-Chief duties.

As Editor-in-Chief, Klaus Preissner was devoted to providing the best quality of science to reflect a balanced selection of basic and clinical research in the field for the readership of this journal. He has been thoughtful and impeccable in his decisions, has extended the borders to many other aspects of vascular biology and medicine, and has achieved a remarkable turn-around and steady increase of the journal's impact factor rising to 3.803 in 2008. Recognising the increasingly broad remit of the world of thrombosis and vascular biology, he introduced a Deputy Editor-in-Chief responsible for clinical studies in 2008. Theme issues on 'highlight topics' have been introduced (1–3), and links with the European Society of Cardiology Working Group on Thrombosis, and – more recently – with the Italian Society of Thrombosis and Hae-

mostasis (SISSET) have been established. One of the recent outputs of the link with the ESC Working Group on Thrombosis, is the publication of an important consensus document on the management of anti-coagulated atrial fibrillation patients who present with an acute coronary syndrome and/or undergo percutaneous coronary intervention/stenting (4; *in this issue*).

Thus, Klaus Preissner has truly been an innovator for the journal. He will continue to be Chairman and Head of the Institute of Biochemistry at the Justus-Liebig-University Giessen, as well as being a spokesman and constructive referee of several research programs funded by the German Research Foundation (DFG). Thus, we pay our tribute to Klaus Preissner for his outstanding service to the journal and its readership. It is an honour for us to follow in his footsteps in striving to extend and promote the journal's influence in the scientific community.

In 2010, *Thrombosis and Haemostasis* moves forward with two Editors-in-Chief, one responsible for basic sciences (Christian Weber) and one for clinical studies (Gregory Lip). This will further emphasise the dual focus on basic and clinical research of the journal. With the appointment of Walter Ageno, Robert Andrews, George Breier, Catherine Hayward, Bernd Jilma, Francois Mach, Bernhard Nieswandt and David Varon as new Section Editors – who now cover a broad spectrum of research fields related to angiogenesis, atherosclerosis, platelet and coagulation disorders and vascular pathobiology, as well as clinical pharmacology – this clearly complements, strengthens and widens the current scope of *Thrombosis and Haemostasis*. We also thank our recently retired editorial board members, for all their hard work and dedication to the journal.

What will 2010 bring? With regard to theme issues in basic science, we will continue to feature focussed review articles as



Christian Weber



Gregory Y. H. Lip

well as proceedings of high level meetings, for example, that based on the 5th European Meeting on Vascular Biology and Medicine (EMVBM) 2009 in Marseille (edited by Francoise Dignat-George and Jose Sampol) or the Factor XII-centred Symposium held in the honour of Oscar D. Ratnoff in Ohio (edited by Alvin Schmaier), both scheduled for early 2010. These specific theme issues will also be paralleled by clinical 'open' theme issues on "Hot Topics in Cardiovascular Cell and Pharmacotherapy" (edited by Karlheinz Peter and Gregory Lip) and "Stem Cells in Vascular Medicine" (edited by Hung-Fat Tse) which are also open to original articles and are scheduled for Spring

Correspondence to:

Prof. C. Weber
Institut für Molekulare Herz-Kreislaufforschung
Universitätsklinikum Aachen
Pauwelsstr. 30, 52072 Aachen, Germany
Tel.: +49 241 808 8692, Fax: +49 241 808 2716
E-mail: cweber@ukaachen.de

or

Professor G. Y. H. Lip
Haemostasis Thrombosis and Vascular Biology Unit
University of Birmingham
Centre for Cardiovascular Sciences
City Hospital, Birmingham B18 7QH, UK
Tel.: +44 121 507 5080, Fax: +44 121 554 4083
E-mail: g.y.h.lip@bham.ac.uk

Thromb Haemost 2010; 103: 1–2

Thrombosis and Haemostasis 103.1/2010

2010. We are continuing with in-depth reviews and clinical focus articles, as well as Pro/Contra articles which debate areas of controversy in thrombosis. Furthermore, we intend to introduce 'Seminars' this year, which would represent more overviews of both basic science and clinical topics, with an educational (and sometimes provocative or controversial) emphasis. Thus, we are confident that the journal will grow and be even more attractive for you as our readership and as authors for submitting your very best work. In turn, we promise high quality peer reviews and rapid turnaround times for the first decision.

On behalf of the editorial board and the whole editorial team we would like once more to express our appreciation for the continued interest and support of our readership, and we thank our dedicated referees for their consistent support of the editorial board in decision making and in the selection of excellent papers. We are truly

grateful for your efforts and maintain our trust in your unbiased and timely reviewing activities in the future. Change is not simply for the sake of change – it is our mission to further increase the impact and to enhance the visibility of *Thrombosis and Haemostasis*. We sincerely hope that you will join us on this exciting journey.



Christian Weber
(Editor-in-Chief, Basic Science)
Aachen, Germany



Gregory Y. H. Lip
(Editor-in-Chief, Clinical Studies)
Birmingham, UK

References

1. Weber C. Chemokines take centre stage in vascular biology. *Thromb Haemost* 2007; 97: 685–687.
2. Braun T, Preissner KT. Cutting edge research for novel therapies of heart and lung diseases. *Thromb Haemost* 2009; 101: 610–612.
3. Weber C. Frontiers in vascular biology: mechanisms of inflammation and immunoregulation in arterial remodelling. *Thromb Haemost* 2009; 102: 188–190.
4. Lip GYH, Huber K, Andreotti F, et al. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting With Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting: A Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association [EHRA] and the European Association of Percutaneous Cardiovascular Interventions [EAPCI]. *Thromb Haemost* 2010; 103: 13–28.